Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
DNA Damage
100%
Immune Escape
100%
Pancreatic Adenocarcinoma
100%
Lung Adenocarcinoma
100%
Reverse Engineering
100%
Predictive Signature
100%
Advanced Lung Adenocarcinoma
75%
High Risk
50%
Tumor
25%
Cancer Patients
25%
Statistical Analysis
25%
Overall Survival
25%
Cisplatin
25%
Response to Therapy
25%
Patients at Risk
25%
Stemness
25%
Transcriptome
25%
Cox Regression
25%
Immune Infiltration
25%
Training Set
25%
Survival Improvement
25%
Validation Set
25%
Path Analysis
25%
Gemcitabine
25%
Multivariate Cox Regression Analysis
25%
Early-stage Lung Cancer
25%
Kaplan-Meier
25%
Clinical Factors
25%
Gene Signature
25%
Recurrence-free Survival
25%
Early Cancer
25%
Biomarker Research
25%
Tailored Treatment
25%
Gene Set Enrichment Analysis
25%
Molecular Traits
25%
Training Test
25%
MHC Class II Antigen Presentation
25%
Cross-validation Analysis
25%
Early Pancreatic Cancer
25%
MHC Class I Antigen Presentation
25%
DNA Repair Deficiency
25%
R Language
25%
FOLFIRINOX
25%
Biochemistry, Genetics and Molecular Biology
DNA Repair
100%
Antigen Presentation
100%
Overall Survival
100%
DNA Damage
100%
MHC Class II
100%
Cisplatin
100%
Cancer Staging
100%
MHC Class I
100%
Gemcitabine
100%
Transcriptome
100%
Recurrence Free Survival
100%
Gene Signature
100%
Biomarker Research
100%
Gene Set Enrichment
100%
Immunology and Microbiology
Antigen Presentation
100%
DNA Damage
100%
Overall Survival
100%
MHC Class II
100%
Cancer Staging
100%
Immune Cell Infiltration
100%
DNA Repair
100%
MHC Class I
100%
Immune Escape
100%
Transcriptome
100%
Recurrence Free Survival
100%